The COVID-19 pandemic involved thousands of scientists, doctors, public health officials, and government leaders across nearly every country. A handful of individuals played outsized roles, from the doctor who first sounded the alarm in Wuhan to the researchers whose decades-old work made rapid vaccines possible. Here are the key people and organizations that shaped the pandemic response.
The Doctor Who Raised the First Alarm
Li Wenliang, a 34-year-old ophthalmologist at Wuhan Central Hospital, was one of the earliest voices to warn about the emerging virus. On December 30, 2019, after the Wuhan municipal health service sent out an internal alert, Li messaged a private group of former medical school classmates on WeChat about seven cases of a SARS-like illness linked to the Huanan Seafood Wholesale Market. He was one of eight people reprimanded by local security officers for “spreading rumours.”
Li later contracted the virus himself while treating patients and died on February 7, 2020. He became an international symbol of the dangers frontline healthcare workers faced and a rallying point for calls for transparency in public health reporting.
The Scientist Who Shared the Virus’s Genetic Code
On January 11, 2020, a consortium led by virologist Yong-Zhen Zhang at the Shanghai Public Health Clinical Center posted the first complete genome sequence of SARS-CoV-2 on the open-access site virological.org. The sequence was also deposited in GenBank, making it freely available to researchers worldwide. This single act was pivotal: within days, labs across the globe began designing diagnostic tests and, critically, the vaccine candidates that would arrive less than a year later.
Global Health Officials Who Coordinated the Response
Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization, led the international public health response. The WHO declared COVID-19 a Public Health Emergency of International Concern on January 30, 2020, when confirmed cases were still mostly concentrated in China. Six weeks later, on March 11, 2020, with more than 80,000 confirmed cases reported worldwide, the WHO formally declared it a global pandemic.
In the United States, Anthony Fauci served as the most visible scientific voice. As director of the National Institute of Allergy and Infectious Diseases, a position he held until December 2022, Fauci advised seven U.S. presidents on public health issues ranging from HIV to pandemic influenza. During COVID-19, he became the public face of the White House Coronavirus Task Force, delivering daily briefings that millions of Americans relied on for guidance on masking, social distancing, and vaccination.
The mRNA Vaccine Pioneers
The Pfizer-BioNTech and Moderna vaccines, the first COVID-19 vaccines authorized in many Western countries, relied on mRNA technology that two researchers had spent more than a decade developing. Katalin Karikó and Drew Weissman discovered how to chemically modify the building blocks of mRNA so that it could be injected into the body without triggering a severe inflammatory response, while still producing the proteins needed to train the immune system. For years their work was considered a scientific dead end, and Karikó struggled to secure funding. It took the urgency of a pandemic for their findings to be deployed at scale. In October 2023, Karikó and Weissman were awarded the Nobel Prize in Physiology or Medicine for discoveries that enabled effective mRNA vaccines against COVID-19.
The Oxford-AstraZeneca Vaccine Team
While mRNA vaccines made headlines in wealthier nations, the Oxford-AstraZeneca vaccine became a workhorse for much of the developing world because it was cheaper to produce and easier to store. Sarah Gilbert, a vaccinologist at the University of Oxford, co-designed the vaccine alongside Catherine Green, who led the team that physically constructed it in the lab. Gilbert and Green later co-authored a book called “Vaxxers,” chronicling their work from the moment they first became aware of the disease on January 1, 2020, through the successful vaccine rollout in spring 2021. The vaccine used a different technology from the mRNA shots, delivering genetic instructions via a harmless modified virus rather than synthetic mRNA.
Operation Warp Speed and the U.S. Government Push
The U.S. government launched Operation Warp Speed (OWS) to compress the typical vaccine development timeline from years to months. Moncef Slaoui, a former pharmaceutical executive, was appointed chief advisor, while General Gustave F. Perna served as chief operating officer, overseeing manufacturing and distribution logistics. Congress directed nearly $10 billion to the effort through supplemental funding, including the CARES Act. Of that, over $6.5 billion went to countermeasure development through the Biomedical Advanced Research and Development Authority (BARDA), and $3 billion supported research through the National Institutes of Health.
The initiative also brought in career scientists to oversee specific areas. Peter Marks at the FDA led the vaccines division, Janet Woodcock led therapeutics, and Bruce Tromberg at the NIH oversaw diagnostics. This combination of military logistics, government funding, and scientific oversight allowed multiple vaccine candidates to be manufactured in parallel with clinical trials, rather than waiting for each phase to finish before starting the next.
International Efforts to Distribute Vaccines
Getting vaccines into arms worldwide required coordination far beyond any single country. COVAX, a historic multilateral initiative, was co-led by Gavi (the Vaccine Alliance), the Coalition for Epidemic Preparedness Innovations (CEPI), and the WHO, with UNICEF serving as a key delivery partner. Operating from 2020 through 2023, COVAX aimed to guarantee fair access to COVID-19 vaccines for every country in the world, regardless of income level. The initiative accelerated both the development and manufacture of vaccines and negotiated advance purchase agreements so that lower-income nations would not be left at the back of the line.
COVAX ultimately delivered billions of doses to 146 countries, though it fell short of its most ambitious targets. Wealthier nations secured their own bilateral deals with vaccine makers, which sometimes left COVAX competing for limited supply during the critical early months of the rollout.